摘要 |
<p>The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-βreceptor agonist or an IFN-γreceptor agonist, for the treatment of cancer.</p> |
申请人 |
CYTOCURE LLC;THE GENERAL HOSPITAL CORPORATION;HAGGERTY, TIMOTHY, J.;KURNICK, JAMES, T.;DUNN, IAN, S. |
发明人 |
HAGGERTY, TIMOTHY, J.;KURNICK, JAMES, T.;DUNN, IAN, S. |